Provided by Tiger Trade Technology Pte. Ltd.

ArTara Therapeutics, Inc.

5.33
+0.16003.09%
Post-market: 5.380.0500+0.94%18:16 EDT
Volume:640.15K
Turnover:3.35M
Market Cap:288.27M
PE:-3.97
High:5.34
Open:5.20
Low:5.14
Close:5.17
52wk High:7.82
52wk Low:2.77
Shares:54.08M
Float Shares:35.46M
Volume Ratio:1.00
T/O Rate:1.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3409
EPS(LYR):-1.3409
ROE:-31.60%
ROA:-20.64%
PB:1.47
PE(LYR):-3.97

Loading ...

CORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health

GlobeNewswire
·
4 hours ago

Protara Therapeutics Inc : H.c. Wainwright Raises Target Price to $27 From $23

THOMSON REUTERS
·
Apr 29

Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT) and Protara Therapeutics (TARA)

TIPRANKS
·
Apr 29

Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health

GlobeNewswire
·
Apr 28

Protara Therapeutics to Present Updated, Interim 12-Month Data From the Phase 2 Advanced-2 Trial of Tara-002 in Bcg-NaÏVe Nmibc Patients at the American Urological Association Annual Meeting

THOMSON REUTERS
·
Apr 28

Press Release: Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting

Dow Jones
·
Apr 28

Protara Therapeutics announces annual shareholder meeting via webcast

Reuters
·
Apr 18

Bayer’s TARA Study: Real‑World Prostate Cancer Data That Could Shape BAYRY’s Outlook

TIPRANKS
·
Apr 17

Protara Chief R&D Officer Jacqueline Zummo sells USD 6,124 common shares

Reuters
·
Apr 10

JonesTrading Remains a Buy on Protara Therapeutics (TARA)

TIPRANKS
·
Apr 07

Protara Therapeutics Highlights Positive TARA-002 Phase 2 Results

TIPRANKS
·
Mar 30

Protara warrants set to expire June 29 after trial endpoint met

Reuters
·
Mar 30

Buy Rating on TARA-002 Backed by Best-in-Class NMIBC Data, FDA-Aligned Phase 3 Strategy, and Solid Cash Runway

TIPRANKS
·
Mar 20

Protara Therapeutics (TARA) Receives a Buy from Oppenheimer

TIPRANKS
·
Mar 11

Protara Therapeutics: Buy Rating on Strong TARA-002 Phase 2 Data, Clear Late-Stage Pipeline Roadmap, and Cash Runway Through 2028

TIPRANKS
·
Mar 11

Protara Q4 net loss widens on higher R&D spend

Reuters
·
Mar 10

BRIEF-Protara Therapeutics Q4 EPS USD -0.37

Reuters
·
Mar 10

Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

THOMSON REUTERS
·
Mar 10

Protara Therapeutics Q4 Operating Expenses USD 19.079 Million

THOMSON REUTERS
·
Mar 10

Protara Therapeutics Q4 Net Income USD -17.307 Million

THOMSON REUTERS
·
Mar 10